• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Puche Luisa

    2/16/24 9:13:55 AM ET
    $ENOB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ENOB alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Puche Luisa

    (Last) (First) (Middle)
    C/O RENOVARO BIOSCIENCES INC.
    9480 NE 2ND AVENUE #73

    (Street)
    MIAMI FL 33138

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    RENOVARO INC. [ RENB ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Financial Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    02/13/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Option to Purchase Common Stock $6.15 02/13/2024 D 60,000 (1) 06/06/2029 Common Stock 60,000 (2) 0 D
    Option to Purchase Common Stock $1.92 02/13/2024 A 60,000 02/13/2024 06/06/2029 Common Stock 60,000 (2) 60,000 D
    Option to Purchase Common Stock $8.58 02/13/2024 D 60,000 (3) 10/26/2031 Common Stock 60,000 (2) 0 D
    Option to Purchase Common Stock $1.92 02/13/2024 A 60,000 02/13/2024 10/26/2031 Common Stock 60,000 (2) 60,000 D
    Option to Purchase Common Stock $2.38 02/13/2024 D 75,000 (4) 07/22/2032 Common Stock 75,000 (2) 0 D
    Option to Purchase Common Stock $1.92 02/13/2024 A 75,000 02/13/2024 07/22/2032 Common Stock 75,000 (2) 75,000 D
    Option to Purchase Common Stock $2.15 02/13/2024 D 80,000 (5) 10/18/2032 Common Stock 80,000 (2) 0 D
    Option to Purchase Common Stock $1.92 02/13/2024 A 80,000 (5) 10/18/2032 Common Stock 80,000 (2) 80,000 D
    Explanation of Responses:
    1. The option vested in three equal installments on January 7, 2019, January 7, 2020 and January 7, 2021.
    2. The transactions reported herein reflect a stock option repricing (the "Option Repricing") effective on February 13, 2024 (the "Repricing Date"). Pursuant to the Option Repricing, which was approved by stockholders on January 25, 2024, the exercise price of all repriced options has been amended to $1.92 per share, the closing price of the Company's common stock, par value $0.0001 per share (the "Common Stock"), on the date of the closing of the Registrant's acquisition of GEDi Cube Intl Ltd. There were no other changes to the terms of the options.
    3. The option vested in three equal installments on October 26, 2021, October 26, 2022 and October 26, 2023.
    4. The option vested on January 22, 2023.
    5. One third of the option vested on October 18, 2023, the remainder of the option vests equally on October 18, 2024 and October 18, 2025.
    /s/ Luisa Puche 02/16/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ENOB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ENOB

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ENOB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Binette Francois

    4 - RENOVARO INC. (0001527728) (Issuer)

    2/16/24 9:44:03 AM ET
    $ENOB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Binette Francois (Amendment)

    3/A - RENOVARO INC. (0001527728) (Issuer)

    2/16/24 9:38:57 AM ET
    $ENOB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Puche Luisa

    4 - RENOVARO INC. (0001527728) (Issuer)

    2/16/24 9:13:55 AM ET
    $ENOB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENOB
    SEC Filings

    View All

    Enochian Biosciences Inc. filed SEC Form 8-K: Other Events

    8-K - RENOVARO INC. (0001527728) (Filer)

    2/16/24 8:35:25 AM ET
    $ENOB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Enochian Biosciences Inc.

    10-Q - RENOVARO INC. (0001527728) (Filer)

    2/14/24 5:17:42 PM ET
    $ENOB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enochian Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Other Events, Unregistered Sales of Equity Securities, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - RENOVARO INC. (0001527728) (Filer)

    2/14/24 4:33:15 PM ET
    $ENOB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENOB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AI Company GEDi Cube and Renovaro Biosciences Announce a Binding, Exclusive Letter of Intent to Merge, Accelerating Fight Against Cancer

    Cutting-edge AI/machine learning technology with validation in humans for early diagnosis of lung cancer In silico detection for 12 additional cancers, including pancreaticMore than 2,600 proprietary biomarker panels Rapidly expanding to other cancers and diseases Innovative biotechnology firm with promising pancreatic cancer results projected to begin human studies for several challenging solid tumors by mid-2024Combination creates potential multiplier effect to accelerate earlier diagnosis, more effective therapy, and precision, in silico drug discovery   LOS ANGELES, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Renovaro BioSciences Inc. (NASDAQ:RENB) (NASDAQ:ENOB), an advanced, pre-clinical biot

    8/9/23 9:00:00 AM ET
    $ENOB
    $RENB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enochian BioSciences Inc. Announces Adjournment of 2023 Annual Stockholder Meeting

    LOS ANGELES, June 23, 2023 (GLOBE NEWSWIRE) -- (NASDAQ:ENOB). Enochian BioSciences Inc., a company developing gene-modified cell immunotherapies for cancer and infectious diseases, wishes to advise that its 2023 Annual Stockholder Meeting (the "Annual Meeting"), which was scheduled to be held yesterday, June 22, 2023 at 12:00 p.m. Eastern Time, was convened and adjourned, without any business being conducted, due to the lack of the required quorum. As a result of the required quorum not being present, the Annual Meeting has been adjourned to 12:00 p.m. (Eastern Time) on Friday July 21, 2023 ("Adjourned Annual Meeting") to allow additional time for the Company's stockholders to vote on the

    6/23/23 5:00:00 PM ET
    $ENOB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enochian BioSciences Announces that its Cancer Platform Remains on Track for Trials in Humans Following FDA Review

    LOS ANGELES, June 08, 2023 (GLOBE NEWSWIRE) -- (NASDAQ:ENOB). Enochian BioSciences Inc. (the Company) announces that it remains confident in submitting an Investigational New Drug Application (IND) for its innovative Cancer Platform in early/mid 2024 following review of comments made by the US Food and Drug Administration on the Company's Pre-IND submission. If successful, that would allow clinical trials to begin by the first half of 2024. The Company's proprietary, novel technology uses cell- and gene-therapy to promote a renewed immune response against solid tumors. The important confirmatory results from two humanized mouse models using our novel dendritic-cell based therapy, indepen

    6/8/23 8:45:00 AM ET
    $ENOB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENOB
    Financials

    Live finance-specific insights

    View All

    Enochian BioSciences Announces Scientific Presentation of Elimination of HBV in Mice with No Evident Toxicity

    LOS ANGELES, June 30, 2021 (GLOBE NEWSWIRE) -- (NASDAQ:ENOB) – Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that Dr. Serhat Gumrukçu, co-founder and inventor of Enochian BioSciences and Director of Seraph Research Institute (SRI), presented data demonstrating daily reduction of Hepatitis B Virus (HBV) until it could no longer be detected by the 8th day. No toxicities to the liver or other tissues were identified. The findings were presented during the prestigious International Liver Conference, and presentations can be found (Link to presentations.) Enochian BioSciences holds the exclusive l

    6/30/21 7:00:00 AM ET
    $ENOB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENOB
    Leadership Updates

    Live Leadership Updates

    View All

    Enochian BioSciences Appoints Dr. Richard Whitley As Senior Scientific Advisor

    LOS ANGELES, July 25, 2022 (GLOBE NEWSWIRE) -- (NASDAQ:ENOB)—Today, Enochian BioSciences (the Company) announced that Dr. Richard (Rich) Whitley, M.D., of the University of Alabama at Birmingham (UAB), will become the Company's Senior Scientific Advisor. A Distinguished Professor of Pediatrics at UAB, Dr. Whitley brings decades of virology research experience to the Company, including clinical research experience to develop antiviral therapies. "We are incredibly excited to bring on Dr. Whitley as a Senior Scientific Advisor," said Enochian's CEO Dr. Mark Dybul. "Rich is not only a talented clinician, but also a well noted researcher whose experience and expertise will be instrumental in

    7/25/22 10:15:16 AM ET
    $ENOB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enochian BioSciences Board Learns of Arrest of Co-Founder and Inventor and Expresses Strong Confidence in the Promising Future of the Company

    The Board learned of the arrest of Dr. Serhat Gumrukçu after the Press Release by the Department of Justice on May 25, 2022;The Board has verified that the incident leading to the arrest occurred prior to the merger which created the Enochian of today, and is completely unrelated to the Company;The Board reviewed the important scientific discoveries of the inventor and the Company's rights with regards to those discoveries, which will be unchangedThe Board confirmed that Dr. Serhat Gumrukçu has had no formal role in the Company, and has no involvement with the Company's strong management, scientific team and collaborations with leaders in the field;Therefore, the Board strongly affirms its c

    5/25/22 4:20:30 PM ET
    $ENOB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enochian BioSciences Announces the Appointment of Executive Vice President of Research and Development with 25 years of Industry Experience

    LOS ANGELES, April 20, 2022 (GLOBE NEWSWIRE) -- Enochian BioSciences (NASDAQ:ENOB). Enochian BioSciences Inc., a company focused on gene-modified cellular and immunotherapies in infectious diseases and cancer, today is announcing the appointment of Dr. François Binette, Ph.D. as Executive Vice President for Research and Development. Dr. Binette brings over 25 years of Advanced Therapy and Regenerative Medicine product development expertise, most recently as Senior VP of Product Development at Lineage Cell Therapeutics where he led multiple innovative allogenic cell therapy programs from discovery to clinical stages and contributed to one of the largest non-cancer cell therapy corporate par

    4/20/22 7:00:00 AM ET
    $ENOB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENOB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Enochian Biosciences Inc. (Amendment)

    SC 13D/A - RENOVARO INC. (0001527728) (Subject)

    2/16/24 6:11:03 PM ET
    $ENOB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Enochian Biosciences Inc. (Amendment)

    SC 13D/A - RENOVARO INC. (0001527728) (Subject)

    2/16/24 3:03:30 PM ET
    $ENOB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Enochian Biosciences Inc. (Amendment)

    SC 13D/A - RENOVARO BIOSCIENCES INC. (0001527728) (Subject)

    1/24/24 4:08:52 PM ET
    $ENOB
    Biotechnology: Pharmaceutical Preparations
    Health Care